Characteristics Associated With Treatment Failure 1 Year After Midurethral Sling in Women With Mixed Urinary Incontinence.


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 10 8 2020
medline: 26 11 2020
entrez: 10 8 2020
Statut: ppublish

Résumé

To evaluate characteristics associated with treatment failure 1 year after midurethral sling in women with mixed urinary incontinence. Four hundred three women who participated in a randomized trial that compared midurethral sling and behavioral and pelvic floor muscle therapy (combined group) against midurethral sling alone for mixed incontinence with 1 year of follow-up data were eligible for this planned secondary analysis. Overall treatment failure was defined as meeting criteria for subjective failure, objective failure, or both. Subjective failure was defined as not meeting the minimal clinically important difference for improvement on the UDI (Urogenital Distress Inventory)-total score (26.1 points). Objective failure was not achieving 70% improvement on mean incontinence episodes of any type per day or having undergone any additional treatment for urinary symptoms at 12 months postoperative. Logistic regression models for treatment failure were constructed. Independent variables included site and treatment group, and clinical and demographic variables based on bivariate comparisons (P<.2). Treatment group interaction effects were evaluated. Previous overactive bladder medication use (unadjusted odds ratio [OR] 2.19, adjusted odds ratio [aOR] 1.89, 95% CI 1.10-3.25), detrusor overactivity on cystometrogram (OR 2.25, aOR 2.72, 95% CI 1.53-4.84), body mass index (OR 1.29, aOR 1.27, 95% CI 1.03-1.57), and Valsalva leak point pressure less than 60 cm H2O (OR 1.96, aOR 3.13, 95% CI 1.65-5.94) were associated with overall failure. Worse UDI urgency scores were associated with failure in the midurethral sling-alone group. Sling type (retropubic vs transobturator) was not associated with failure. Certain clinical and urodynamic variables are associated with treatment failure after midurethral sling among women with mixed urinary incontinence. Women with more severe urgency symptoms at baseline may benefit from perioperative behavioral and pelvic floor muscle therapy combined with midurethral sling. This information is helpful for counseling women with mixed incontinence who are considering surgery. ClinicalTrials.gov, NCT01959347.

Identifiants

pubmed: 32769647
doi: 10.1097/AOG.0000000000003989
pmc: PMC7483953
mid: NIHMS1594873
pii: 00006250-202009000-00007
doi:

Banques de données

ClinicalTrials.gov
['NCT01959347']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Retracted Publication

Langues

eng

Sous-ensembles de citation

IM

Pagination

482-491

Subventions

Organisme : NICHD NIH HHS
ID : U10 HD041261
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD069013
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD054215
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD054214
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD069031
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD069013
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD041267
Pays : United States
Organisme : NICHD NIH HHS
ID : U24 HD069031
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD069025
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD069006
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD069010
Pays : United States

Commentaires et corrections

Type : RetractionIn

Références

Obstet Gynecol. 2008 Mar;111(3):611-21
pubmed: 18310363
Int Urogynecol J. 2017 Apr;28(4):621-628
pubmed: 27686569
Int Urogynecol J. 2017 May;28(5):687-696
pubmed: 28321473
Int Urogynecol J. 2016 Oct;27(10):1479-90
pubmed: 27287818
N Engl J Med. 2012 May 24;366(21):1987-97
pubmed: 22551104
N Engl J Med. 2010 Jun 3;362(22):2066-76
pubmed: 20479459
J Urol. 2011 Aug;186(2):597-603
pubmed: 21683412
Female Pelvic Med Reconstr Surg. 2019 Nov/Dec;25(6):448-452
pubmed: 29734200
Neurourol Urodyn. 2010;29(1):213-40
pubmed: 20025020
Obstet Gynecol. 2011 Apr;117(4):913-921
pubmed: 21422865
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Oct;19(10):1359-62
pubmed: 18491026
J Urol. 2004 Oct;172(4 Pt 1):1370-3
pubmed: 15371847
J Urol. 2006 Aug;176(2):627-32; discussion 632
pubmed: 16813906
Am J Obstet Gynecol. 2008 Dec;199(6):666.e1-7
pubmed: 19084098
J Urol. 2017 Oct;198(4):875-883
pubmed: 28625508
JAMA. 2019 Sep 17;322(11):1066-1076
pubmed: 31529007
Qual Life Res. 1994 Oct;3(5):291-306
pubmed: 7841963
Am J Obstet Gynecol. 2003 Jul;189(1):98-101
pubmed: 12861145
Int Urogynecol J. 2014 Oct;25(10):1303-12
pubmed: 25091925

Auteurs

Vivian W Sung (VW)

Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, Rhode Island; the Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama; the Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; the Division of Urogynecology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina; the Division of Female Pelvic Medicine & Reconstructive Surgery, Department of Obstetrics & Gynecology, Kaiser Permanente, Downey, California; the Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania; the Division of Urogynecology, Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico; the Center for Urogynecology and Reconstructive Pelvic Surgery, Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio; the Department of Physical Therapy, Rangos School of Health Sciences, Duquesne University, Pittsburgh, Pennsylvania; the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; and Social, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH